Status:
RECRUITING
Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease
Lead Sponsor:
Medical University Innsbruck
Conditions:
Ulcerative Colitis (UC)
IBD-unclassified (IBD-U)
Eligibility:
All Genders
Up to 18 years
Brief Summary
Inflammatory Bowel Diseases (IBD), which include Crohn's disease (CD), ulcerative colitis (UC), and the unclassified form referred to as indeterminate colitis, are most commonly diagnosed during adole...
Eligibility Criteria
Inclusion
- Pediatric patients with an Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis, and IBD-unclassified) being under 18 years of age
- Treatment with Infliximab, Adalimumab, Vedolizumab, or Ustekinumab during induction or maintenance phase
Exclusion
- \-- Patients with primary (congenital) immunodeficiency
Key Trial Info
Start Date :
February 17 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 17 2030
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06954311
Start Date
February 17 2025
End Date
February 17 2030
Last Update
May 1 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Landeskrankenhaus Feldkirch
Feldkirch, Austria, 6800
2
Universitätsklinikum Graz / Medizinische Universität Graz
Graz, Austria, 8036
3
Medical University of Innsbruck
Innsbruck, Austria, 6020
4
Klinikum Klagenfurt
Klagenfurt, Austria, 9020